Klein Pavlis & Peasley Financial Inc. Takes $237,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Klein Pavlis & Peasley Financial Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,159 shares of the medical equipment provider’s stock, valued at approximately $237,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after purchasing an additional 100 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares in the last quarter. Finally, Moody National Bank Trust Division lifted its position in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $110.30 on Monday. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a market cap of $7.65 billion, a PE ratio of 16.84 and a beta of 0.50. The company’s 50-day moving average is $107.32 and its two-hundred day moving average is $93.16.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.40 earnings per share. Equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Activity at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares of the company’s stock, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,981 shares of company stock worth $2,689,156 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. B. Riley upped their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Leerink Partners upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.